Sally Church - FriendFeed

Sign in or Join FriendFeed

FriendFeed is the easiest way to share online. Learn more »

ASH 2012 update on ARRY-520 in multiple myeloma - http://pharmastrategyblog.com/2013...

March 1 from Pharma Strategy Blog - Comment - Like - Share

Will biomarkers revolutionalise treatment with tivozanib? - http://pharmastrategyblog.com/2013...

February 25 from Pharma Strategy Blog - Comment - Like - Share

ASCO GU update on tivozanib in advanced clear cell renal cancer - http://pharmastrategyblog.com/2013...

February 21 from Pharma Strategy Blog - Comment - Like - Share

Tumor Lysis Syndrome – what is it and why is it important in cancer research? - http://pharmastrategyblog.com/2013...

February 18 from Pharma Strategy Blog - Comment - Like - Share

Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal - http://pharmastrategyblog.com/2013...

February 15 from Pharma Strategy Blog - Comment - Like - Share

Making a difference in pancreatic cancer – an interview with Dr Hedy Lee Kindler - http://pharmastrategyblog.com/2013...

February 12 from Pharma Strategy Blog - Comment - Like - Share

Will ASCO GI herald a new era for pancreatic cancer? - http://pharmastrategyblog.com/2013...

January 24 from Pharma Strategy Blog - Comment - Like - Share

Effectively targeting KRAS in lung cancer with a MEK inhibitor - http://pharmastrategyblog.com/2012...

November 29 from Pharma Strategy Blog - Comment - Like - Share

Time to rethink cancer clinical trials strategy? - http://pharmastrategyblog.com/2012...

November 27 from Pharma Strategy Blog - Comment - Like - Share

Zaltrap – a simple dosing error or not? - http://pharmastrategyblog.com/2012...

November 9 from Pharma Strategy Blog - Comment - Like - Share

Free Software liked this

Update on KRAS in pancreatic cancer - http://pharmastrategyblog.com/2012...

October 12 from Pharma Strategy Blog - Comment - Like - Share

Prospect of Abraxane in Pancreatic Cancer excites ESMO 2012 - http://pharmastrategyblog.com/2012...

September 30 from Pharma Strategy Blog - Comment - Like - Share

Update on bavituximab in non-squamous lung cancer - http://pharmastrategyblog.com/2012...

September 11 from Pharma Strategy Blog - Comment - Like - Share

ASCO 2012 Update 2: Overcoming resistance in metastatic melanoma - http://pharmastrategyblog.com/2012...

June 29, 2012 from Pharma Strategy Blog - Comment - Like - Share

A surfeit of riches in CLL and NHL: on bruton kinase and PI3K delta inhibitors - http://pharmastrategyblog.com/2012...

June 27, 2012 from Pharma Strategy Blog - Comment - Like - Share

ASCO 2012 Update 1: Advanced Lung Cancer - http://pharmastrategyblog.com/2012...

June 26, 2012 from Pharma Strategy Blog - Comment - Like - Share

Interested in the PI3K-AKT-mTOR pathway in cancer research? - http://pharmastrategyblog.com/2012...

June 20, 2012 from Pharma Strategy Blog - Comment - Like - Share

Aggregating the 2012 ASCO tweets - http://pharmastrategyblog.com/2012...

June 1, 2012 from Pharma Strategy Blog - Comment - Like - Share

Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone - http://pharmastrategyblog.com/2012...

May 25, 2012 from Pharma Strategy Blog - Comment - Like - Share

Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases - http://pharmastrategyblog.com/2012...

May 22, 2012 from Pharma Strategy Blog - Comment - Like - Share

Reflections of a Medical Oncologist on AACR 2012 - http://pharmastrategyblog.com/2012...

May 18, 2012 from Pharma Strategy Blog - Comment - Like - Share

ASCO 2012 Preview – Highlights of key data emerging from Chicago - http://pharmastrategyblog.com/2012...

May 15, 2012 from Pharma Strategy Blog - Comment - Like - Share

ASCO 2012 Acronym Mania! - http://pharmastrategyblog.com/2012...

May 14, 2012 from Pharma Strategy Blog - Comment - Like - Share

Ribonucleases (RNase) – clinical applications for cancer therapy - http://pharmastrategyblog.com/2012...

May 1, 2012 from Pharma Strategy Blog - Comment - Like - Share

Ribonucleases (RNase) what are they and why are they relevant to cancer? - http://pharmastrategyblog.com/2012...

April 30, 2012 from Pharma Strategy Blog - Comment - Like - Share

Highlights of AACR 2012 – Part 3 - http://pharmastrategyblog.com/2012...

April 23, 2012 from Pharma Strategy Blog - Comment - Like - Share

Highlights of AACR 2012 – Part 2 - http://pharmastrategyblog.com/2012...

April 18, 2012 from Pharma Strategy Blog - Comment - Like - Share

Highlights of AACR 2012 – Part 1 - http://pharmastrategyblog.com/2012...

April 17, 2012 from Pharma Strategy Blog - Comment - Like - Share

American Society for Cancer Research Meeting 2012 - http://pharmastrategyblog.com/2012...

March 31, 2012 from Pharma Strategy Blog - Comment - Like - Share

On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer - http://pharmastrategyblog.com/2012...

March 23, 2012 from Pharma Strategy Blog - Comment - Like - Share

Other ways to read this feed: